Scorr-Insert
X

Find Oncology Drugs in Phase II Clinical Development in CANADA

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AB-16B5,Docetaxel Trihydrate

            Therapeutic Area: Oncology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 21, 2020

            Details:

            Alethia to start a clinical trial of AB-16B5 in combination with docetaxel in subjects with metastatic non-small cell lung cancer who have experienced disease progression following treatment with a platinum-containing doublet treatment and an anti-PD1 or PD-L1.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TLD-1433

            Therapeutic Area: Oncology

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 19, 2020

            Details:

            Study II utilizes the Therapeutic Dose of the Study Drug (TLD-1433, Theralase's patented PDC), in conjunction with the Study Device (TLC-3200 Medical Laser System) intended to deliver a safe and effective treatment to patients inflicted with BCG-Unresponsive NMIBC.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TLD-1433

            Therapeutic Area: Oncology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 20, 2020

            Details:

            Enrollment of new patients and conducting the first treatment procedure in the Company's Phase II Non-Muscle Invasive Bladder Cancer clinical study has been temporarily placed on hold.

            IMV

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DPX-Survivac,Cyclophosphamide,Epacadostat

            Therapeutic Area: Oncology

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 25, 2020

            Details:

            First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor.

            IMV

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DPX-Survivac

            Therapeutic Area: Oncology

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 20, 2020

            Details:

            The Phase 2 study is evaluating IMV's lead compound, DPX-Survivac, in patients with advanced recurrent ovarian cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ZW25

            Therapeutic Area: Oncology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: J.P. Morgan Securities

            Deal Size: $279.0 million Upfront Cash: Undisclosed

            Deal Type: MPO January 22, 2020

            Details:

            The company intends to use the net proceeds to accelerate & expand the global development of ZW25 both as a single agent and in combination with other anti-cancer agents & the clinical development of ZW49.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ZW25,Palbociclib,Fulvestrant

            Therapeutic Area: Oncology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 12, 2020

            Details:

            Zymeworks’ HER2-targeted bispecific antibody ZW25 is being evaluated in combination with Pfizer’s Ibrance. Zymeworks will sponsor the study, and Pfizer will provide palbociclib.